Developing Student Collaborations across Disciplines, Distances, and Institutions

Because quantitative biology requires skills and concepts from a disparate collection of different disciplines, the scientists of the near future will increasingly need to rely on collaborations to produce results. Correspondingly, students in disciplines impacted by quantitative biology will need to be taught how to create and engage in such collaborations. In response to this important curricular need, East Tennessee State University and Georgia Technological University/Emory University cooperated in an unprecedented curricular experiment in which theoretically oriented students at East Tennessee State designed biophysical models that were implemented and tested experimentally by biomedical engineers at the Wallace H. Coulter Department of Biomedical Engineering at Georgia Technological University and Emory University. Implementing the collaborations between two institutions allowed an assessment of the student collaborations from before the groups of students had met for the first time until after they had finished their projects, thus providing insight about the formation and conduct of such collaborations that could not have been obtained otherwise

Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases

Minna Allarakhia Department of Management Sciences, University of Waterloo, Waterloo, ON, Canada Abstract: Repurposing has the objective of targeting existing drugs and failed, abandoned, or yet-to-be-pursued clinical candidates to new disease areas. The open-source model permits for the sharing of data, resources, compounds, clinical molecules, small libraries, and screening platforms to cost-effectively advance old drugs and/or candidates into clinical re-development. Clearly, at the core of drug-repurposing activities is collaboration, in many cases progressing beyond the open sharing of resources, technology, and intellectual property, to the sharing of facilities and joint program development to foster drug-repurposing human-capacity development. A variety of initiatives under way for drug repurposing, including those targeting rare and neglected diseases, are discussed in this review and provide insight into the stakeholders engaged in drug-repurposing discovery, the models of collaboration used, the intellectual property-management policies crafted, and human capacity developed. In the case of neglected tropical diseases, it is suggested that the development of human capital be a central aspect of drug-repurposing programs. Open-source models can support human-capital development through collaborative data generation, open compound access, open and collaborative screening, preclinical and possibly clinical studies. Given the urgency of drug development for neglected tropical diseases, the review suggests elements from current repurposing programs be extended to the neglected tropical diseases arena. Keywords: repurposing, open source, rare diseases, neglected tropical diseases, models of collaboration, human-capacity developmen

Analyzing and organizing nanotechnology development: Application of the institutional analysis development framework to nanotechnology consortia

Governments and companies around the globe have embraced nanotechnology as a strategically critical pan industrial technology. Many view it as one of the essential foundation technology bases of the next Schumpeterian wave. A number of commercial and government sponsored groups have developed a variety of consortia centered on the commercial promise of nanotechnology. Yet the optimal management of these consortia has proven elusive to the point that some suggest that they cannot be managed at all. If these consortia are important, and their effective management crucial, then there is cause for concern. We utilize the case study method to create a nanotechnology consortia management diagnostic model based on institutional analysis development (IAD). Nanotechnology consortia are formed for a variety of purposes and their stakeholders include governments, industries, large firms, SME, entrepreneurial enterprises, and supporting firms